1 Department of PharmD, CMR College of Pharmacy, Hyderabad, India.
2 Students, Department of PharmD, CMR College of Pharmacy, Hyderabad, India.
3 Principal, CMR College of Pharmacy, Hyderabad, India.
World Journal of Biology Pharmacy and Health Sciences, 2025, 22(03), 602–605
Article DOI: 10.30574/wjbphs.2025.22.3.0601
Received on 06 May 2025; revised on 13 June 2025; accepted on 16 June 2025
The rare systemic autoimmune disease known as antiphospholipid syndrome (APS) is typified by persistent antiphospholipid antibodies (aPL) along with obstetric morbidity, recurrent thrombosis in the veins and/or arteries, and other non-thrombotic related complications. Obesity, diabetes, hypertension, and cardiovascular diseases are among the long-term health problems that children from difficult pregnancies may be more susceptible to, which could impact their wellbeing both during childhood and into adulthood. Antiphospholipid antibodies' precise etiology is unknown. Being an autoimmune disease, APS causes antibodies to target healthy molecules such as phospholipids, which interferes with coagulation and makes the patient more prone to thrombophilia. The cornerstones of the current preventative treatment standard for APS are anticoagulation and antiplatelet therapy. One significant preventable cause of early pregnancy loss is APS. Preventing obstetric complications requires early risk assessment and individualized treatment, which may include vitamin D, folic acid, and aspirin.
Autoimmune disease; Thrombophilia; Antiphospholipid antibodies (aPL); Coagulation; Obstetric complications
Preview Article PDF
Dr. Pasupuleti Kishore Kumar, Thokala Ruchitha, Pasumala Varun, Chinta Rohit Kumar, Dr. Tadikonda Rama Rao. Antiphospholipid syndrome: Autoimmunity and thrombosis. World Journal of Biology Pharmacy and Health Sciences, 2025, 22(03), 602-605; Article DOI: https://doi.org/10.30574/wjbphs.2025.22.3.0601.